COVID Wasn’t Telehealth’s Shining Moment.

Telehealth didn’t win because of COVID.

It won because regulation moved.

And then—just as quickly—started moving back.

That’s the part most people miss.

The standard narrative is simple: COVID overwhelmed the healthcare system, and telehealth stepped in to fill the gap. Hospitals were full. Clinics shut their doors. Patients still needed care. So providers turned to virtual delivery—and adoption surged.

That story is true.

It’s also incomplete.

Because it gives technology too much credit—and ignores the real driver.

COVID didn’t just accelerate telehealth adoption. It collapsed a decade of regulatory resistance into a matter of weeks.

Reimbursement rules were loosened. Licensing barriers were softened. Restrictions on where and how care could be delivered were lifted. What had been a slow, politically constrained evolution suddenly became an emergency rewrite.

I saw this firsthand, working across 27 states as telehealth rules were rewritten in real time.

And the result was immediate:

Telehealth didn’t just grow.
It cleared the barriers that had been holding it back.

But the real story of telehealth begins after the emergency ends.

Because once the system proved it could work, the question changed:

Not “Can we do this?”

But:

“Who controls it—and who gets paid?”

That’s when the rollback began.

States revisited emergency rules. Payers tightened reimbursement. Regulators raised concerns around fraud, quality, and cost.

On the surface, it looked like a debate about patient care.

In reality, it was something more predictable:

A rebalancing of power in a system where regulation defines winners.

Today, technology has already won.

Virtual care is not going away.

But the next generation of telehealth companies won’t be defined by product. They’ll be defined by how they navigate three structural constraints.

First: reimbursement.
The era of blanket flexibility is over. Programs are being extended, modified, and clawed back in pieces. The question is no longer whether care can be delivered virtually—it’s whether that care is durably reimbursable.

Second: licensing.
Care is still bounded by state lines. Efforts like the Interstate Medical Licensure Compact reduce friction—but don’t remove it. Scale requires regulatory fluency, not just distribution.

Third: modality.
Video visits are already commoditized. The next wave—remote patient monitoring, asynchronous care, and hybrid delivery—sits in areas where policy is still forming.

That’s where the window is.

Two to five years before true clarity.

The first wave of telehealth was about access.

The second wave is about control.

And control, in healthcare, is determined by policy.

COVID didn’t create telehealth. It exposed what happens when regulation gets out of the way—and what follows when it comes back.

The companies that win from here won’t be the ones that scaled the fastest during the pandemic.

They’ll be the ones that built for the system that came after it.

This is what we mean when we say: Regulation isn’t risk. It’s the signal.